BioNxt Solutions Inc. (BNXTF)
OTCMKTS · Delayed Price · Currency is USD
0.4672
+0.0481 (11.47%)
Feb 11, 2026, 9:30 AM EST
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 11.26K CAD in the quarter ending September 30, 2025, a decrease of -34.17%. This brings the company's revenue in the last twelve months to 15.82K, down -62.34% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
15.82K CAD
Revenue Growth
-62.34%
P/S Ratio
4,702.56
Revenue / Employee
n/a
Employees
n/a
Market Cap
53.42M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| The Cannabist Company Holdings | 349.84M |
| Jushi Holdings | 260.43M |
| MariMed | 157.38M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
| Growth Stalk Holdings | 583.34K |
BioNxt Solutions News
- 7 days ago - BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery - Accesswire
- 17 days ago - BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion - Accesswire
- 22 days ago - BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS) - Accesswire
- 24 days ago - BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF - Accesswire
- 2 months ago - Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies - Accesswire
- 2 months ago - BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia - Accesswire
- 2 months ago - BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments - Accesswire
- 3 months ago - BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform - Accesswire